These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22035432)

  • 61. Rheumatoid arthritis: Obesity impairs efficacy of anti-TNF therapy in patients with RA.
    González-Gay MA; González-Juanatey C
    Nat Rev Rheumatol; 2012 Nov; 8(11):641-2. PubMed ID: 23007743
    [No Abstract]   [Full Text] [Related]  

  • 62. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.
    Jani M; Dixon WG; Chinoy H
    Rheumatology (Oxford); 2018 Nov; 57(11):1896-1907. PubMed ID: 29325166
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Frequency of hospitalization and severe events in 497 spondylarthritis patients treated with anti-TNF drugs: comparisons with 423 RA patients.
    Gérard-Benoist S; Leux C; Le Goff B; Maugars Y; Berthelot JM
    Joint Bone Spine; 2012 Mar; 79(2):204-5. PubMed ID: 22088930
    [No Abstract]   [Full Text] [Related]  

  • 64. Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus.
    Todoerti M; Favalli EG; Iannone F; Olivieri I; Benucci M; Cauli A; Mathieu A; Santo L; Minisola G; Lapadula G; Bucci R; Gremese E; Caporali R
    Rheumatology (Oxford); 2018 Oct; 57(57 Suppl 7):vii42-vii53. PubMed ID: 30289539
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis.
    Fang YF; Liu JR; Chang SH; Kuo CF; See LC
    Int J Rheum Dis; 2022 Nov; 25(11):1254-1262. PubMed ID: 35923107
    [TBL] [Abstract][Full Text] [Related]  

  • 66. One year in review: novelties in the treatment of rheumatoid arthritis.
    Guidelli GM; Barskova T; Brizi MG; Lepri G; Parma A; Talarico R; Cantarini L; Frediani B
    Clin Exp Rheumatol; 2015; 33(1):102-8. PubMed ID: 25719499
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The relationship between cancer and rheumatoid arthritis: still a large research agenda.
    Love T; Solomon DH
    Arthritis Res Ther; 2008; 10(3):109. PubMed ID: 18495048
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis.
    Leandro MJ
    Arthritis Res Ther; 2009; 11(5):128. PubMed ID: 19818166
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer.
    Assassi S
    BMJ; 2016 Jan; 352():i472. PubMed ID: 26822198
    [No Abstract]   [Full Text] [Related]  

  • 70. The role of the determination of the CD20 antigen through quantitative flow cytometry in complex cases of rheumatoid arthritis treated with anti-TNF-alpha.
    Hobi A; Bihl T; Fellay B; Waldburger M
    Rheumatol Int; 2006 Oct; 26(12):1161-2. PubMed ID: 16799779
    [No Abstract]   [Full Text] [Related]  

  • 71. Miliary nodularity in a patient receiving TNF inhibitors is not always miliary tuberculosis.
    Haroon M; Cushen B; Veale D
    J Rheumatol; 2012 Mar; 39(3):651-2. PubMed ID: 22383353
    [No Abstract]   [Full Text] [Related]  

  • 72. One year in review 2016: novelties in the treatment of rheumatoid arthritis.
    Calabrò A; Caterino AL; Elefante E; Valentini V; Vitale A; Talarico R; Cantarini L; Frediani B
    Clin Exp Rheumatol; 2016; 34(3):357-72. PubMed ID: 27268779
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use.
    Hazes JM; Coulie PG; Geenen V; Vermeire S; Carbonnel F; Louis E; Masson P; De Keyser F
    Rheumatology (Oxford); 2011 Nov; 50(11):1955-68. PubMed ID: 21890617
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical repercussions of introducing biological therapies: the well-controlled patient.
    Tornero-Molina J
    Reumatol Clin; 2015; 11(3):131-2. PubMed ID: 25769793
    [No Abstract]   [Full Text] [Related]  

  • 75. Small molecular compounds in development for rheumatoid arthritis.
    van Vollenhoven RF
    Curr Opin Rheumatol; 2013 May; 25(3):391-7. PubMed ID: 23492738
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?
    Clark DA
    Inflammopharmacology; 2013 Apr; 21(2):125-7. PubMed ID: 23138614
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Production of TNF by monocytes of patients with early rheumatoid arthritis is increased.
    Leirisalo-Repo M; Paimela L; Jäättelä M; Koskimies S; Repo H
    Scand J Rheumatol; 1995; 24(6):366-71. PubMed ID: 8610221
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs.
    Chen JJ; Dewdney N; Lin X; Martin RL; Walker KA; Huang J; Chu F; Eugui E; Mirkovich A; Kim Y; Sarma K; Arzeno H; Van Wart HE
    Bioorg Med Chem Lett; 2003 Nov; 13(22):3951-4. PubMed ID: 14592482
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Advances in the treatment of inflammatory arthritis.
    Pisetsky DS; Ward MM
    Best Pract Res Clin Rheumatol; 2012 Apr; 26(2):251-61. PubMed ID: 22794097
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Predicting the future of anti-tumor necrosis factor therapy.
    Verweij CL
    Arthritis Res Ther; 2009; 11(3):115. PubMed ID: 19591638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.